Purdue Pharma
Purdue Pharma OxyContin Marketing
Estimated impact: $8.3B
Purdue Pharma aggressively marketed OxyContin as a low-addiction-risk painkiller, contributing to the opioid epidemic that has killed over 500,000 Americans. The company knew its claims about addiction risk were false but continued its marketing campaign for over two decades, driven by confirmation bias around its own flawed studies.
Decision context
Whether to market OxyContin with claims of low addiction potential based on limited and misleading evidence, and whether to continue aggressive sales tactics as addiction reports mounted.
Decision anatomy
Red = risk factor present · Green = protective factor present
The analysis below was produced from the pre-decision document only. No hindsight. This is what the platform would have surfaced if it had been running at the time.
“Purdue Pharma's 1996 OxyContin launch materials cited a 1980 Porter & Jick letter-to-the-editor in NEJM claiming 'less than 1 percent' of hospitalized patients receiving opioids became addicted. The letter was a single-paragraph retrospective observation not designed or peer-reviewed as an addiction-risk study. Purdue's sales force training materials used this citation as the foundation for the claim that OxyContin had low addiction potential. Internal documents later released in Commonwealth v. Purdue (2019) showed the Sackler family was aware by 2001 of widespread diversion and addiction but expanded marketing intensity rather than reducing it.”
Source: DOJ Settlement with Purdue Pharma (2020); Commonwealth of Massachusetts v. Purdue Pharma, Complaint 18-1808 (2019); Keefe, "Empire of Pain" (2021)
Red flags detectable at decision time
- 1980 Porter & Jick letter cited as addiction-risk evidence — not a study, not designed for that question
- Marketing claims outpaced clinical addiction-risk evidence by orders of magnitude
- Internal awareness by 2001 of diversion/addiction epidemic documented in sales force communications
- Sales incentive structures rewarded volume over appropriate prescribing patterns
- Sackler family took $10B+ in distributions while litigation liability mounted — extracting value ahead of settlement
Cognitive biases the platform would have flagged
Hypothetical analysis
DI would flag Purdue's use of Porter & Jick as the canonical selective-perception failure. A bias-adjusted clinical evidence review would have recognized that a 5-sentence retrospective letter cannot carry the weight of a blockbuster-drug safety claim. The organizational decision process failure runs deeper: internal documents showing awareness of real-world harm paired with *expanded* marketing intensity is the pattern that distinguishes negligence from intentional maximization of harm. A working decision-intelligence review would have required annual independent epidemiological updates as a marketing precondition.
Biases present in the decision
★ Primary driver · Severity estimated from bias type and decision outcome
Toxic combinations
Reference class base rates
Across all 143 curated case studies in our library:
Lessons learned
- Confirmation bias in interpreting addiction data allowed Purdue to maintain claims that contradicted real-world evidence for over two decades.
- Loss aversion around a profitable product line can cause companies to ignore catastrophic societal harm.
- Regulatory capture and aggressive lobbying can delay corrective action by years, amplifying public health damage.
Source: DOJ Settlement with Purdue Pharma (2020); Patrick Radden Keefe, "Empire of Pain" (2021) (Case Study)
We caught these patterns in Purdue Pharma's own record — before the outcome.
See the full hindsight-stripped auditwe ran — no login, no card. Then run the same 60-second audit on your own next memo.
Or leave your email, we'll run a strategic memo of your choosing and send the readout within a business day.
Workflows that fire on decisions like Purdue Pharma’s
The same Recognition-Rigor Framework that documents this case audits memos in the same shape — before the outcome forces the lesson.